The purpose of this non-confirmatory study is to determine if SOM230 has adequate efficacy and safety to warrant further clinical development in cluster headache (CH). This study will have two parts. Part A will be a parallel design SOM230 vs. Placebo, and following an observed signal in Part A at an interim analysis, Part B of the study will be a comparison of SOM230 to sumatriptan.
High-flow oxygen was proven to relieve cluster headache attacks within 15 minutes for nearly 80% of attacks with no serious side effects in a controlled clinical study (see the JAMA High-flow Oxygen Study). In fact, oxygen is considered to be the safest method of treating acute cluster headache attacks. The approach is to use 100% pure oxygen at a flow rate of 12-15 lpm, sometimes higher, through a non-rebreather mask for approximately 15 minutes or until the attack is stopped. Although that sounds pretty straightforward, learning how to use high-flow oxygen for quick relief takes some know how and practice. On this page, we describe how to get it, how to use it, and how to be safe with oxygen in the home.
There are two disability programs available through the Social Security Administration: Social Security Disability Insurance and Supplemental Security Income. SSDI is paid for by you through your payroll deductions. SSI is a program managed by the Social Security Administration that makes payments to people with low income who are age 65 or older, are blind, or have a disability. SSI is funded from the general government budget. Do not confuse SSI with SSDI – they are entirely different programs.
There are many types of private disability insurances that may be purchased by individuals or by companies on behalf of employees as a component of their benefits package. For example, if you are a sole proprietor of your own business, you may purchase Key Person disability insurance or Business Overhead Expense insurance to ensure that operations are maintained should you become disabled. Short-term disability insurance policies are typically held by larger companies on behalf of their employees so they may cover employee income should the employee become temporarily disabled due to an injury or illness incurred off the job. Long-term disability insurance held by an individual or through a company plan is designed to cover a portion of employee income should you become disabled for an indefinite period of time beyond the term of any existing short-term disability plan. Long-term disability plans may be effective for a couple of years or up to retirement age.
Cluster headaches can be very debilitating and at some point you may begin to question whether or not it makes sense to continue working. Generally speaking, episodic cluster headaches would not qualify as a disability in the eyes of the government, but they may justify a short-term leave from work. Chronic cluster headaches that have endured for a year or more and are debilitating may justify a longer absence from work or even full disability.
Welcome to our New Patient Guide, where you will learn what cluster headache is, how it is diagnosed & treated, and what you can do to manage this painful condition. You’ll quickly discover there is no “silver bullet” to stop the pain of cluster headaches. In fact, in many cases it takes so long to come to a diagnosis that you may have already been through several drug trials with your physician or neurologist in order to rule out other maladies. This is not at all surprising because cluster headaches are a primary headache type. In order to diagnose a primary headache type, your doctor must first rule out secondary headache types, including headaches caused by trauma, lesion, or tumor. This is for your safety, but it can certainly be frustrating going through the various diagnostics with no real pain relief.
Calcitonin gene-related peptide (CGRP) is a validated target for the treatment of episodic migraine. Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine.
Cluster headaches (CHs) are one of the most debilitating of all the identified headache syndromes. Their pathogenesis is poorly understood, which has made their treatment challenging. Various medicines and modalities have been put forth in an effort to minimize the symptoms, but none have proven to be consistently reliable.
Repeated chronic inflammation, such as under circumstances of ruptured Rathke’s cleft cyst(RCC), is known as the fundamental basis of various pathological changes including neoplastic change,therefore to examine accurate incidence of pituitary adenomas is important for the preventive medicine.
Since its discovery, Onabotulinum toxins have been tried for the treatment of various head, neck and face pain syndromes. The end result of controlled clinical trials was that there was not clear evidence for use in many of the common primary and secondary headaches. In chronic migraine, affecting 1-2% of the population, a fixed site and fixed dose treatment approach was shown to be superior to placebo and was approved for use. In this review, evidence for that use and the history leading to it is described.